Lv6
2310 积分 2022-12-09 加入
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial
11天前
已完结
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial
11天前
已完结
Faculty Opinions recommendation of Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
11天前
已关闭
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer
11天前
已完结
Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
11天前
已关闭
A140 plus mFOLFOX6 compared with cetuximab plus mFOLFOX6 for first-line RAS wild-type metastatic colorectal cancer: A randomized clinical trial
2个月前
已完结
[Management of ocular adverse events associated with antibody-drug conjugates in the treatment of solid tumors: a consensus statement from Chinese experts (2025 edition)]
2个月前
已完结
Human Papillomavirus Detectability and Cervical Cancer Prognosis: A Systematic Review and Meta-analysis
2个月前
已完结
Clinicopathological and prognostic significance of immunophenotypic characterization of endocervical adenocarcinoma using CLDN18, CDH17, and PAX8 in association with HPV status
2个月前
已完结
Human Papillomavirus Detectability and Cervical Cancer Prognosis
2个月前
已完结
皖公网安备34019202002308
